Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Tumor Growth Blocked in Mice by Suppressing Antioxidants in Cancer Cells

By BiotechDaily International staff writers
Posted on 11 Dec 2013
Print article
Many cancers have adapted to deal with the high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1 (SOD1), is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy.

In the December 2, 2013, issue of the Journal of Clinical Investigation, Dr. Navdeep Chandel and colleagues from Northwestern University (Evanston, IL, USA) reported the effects of a SOD1 pharmacologic suppressor on non-small-cell lung cancer (NSCLC) cells. The inhibitor, called ATN-224, blocked the growth of human NSCLC cells in culture, and triggered their death. The researchers also discovered that ATN-224 inhibited other antioxidant proteins, which caused high levels of hydrogen peroxide inside the cells. Cancer cells’ capability to generate hydrogen peroxide was required for ATN-224-dependent effects, because hydrogen peroxide activated cell death pathways.

ATN-224, moreover, triggered cancer cell death and decreased tumor sizes in a mouse model of lung adenocarcinoma. ATN-224-dependent effects in lab mice were enhanced when the inhibitor was used in combination with another drug that activates programmed cell death.

These new findings indicate that antioxidant suppression may be a feasible chemotherapeutic strategy.

Related Links:

Northwestern University



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.